Public Companies
Seelos Downgraded After Phase 2 Trial Failure
Cantor Fitzgerald, in reaction to the news, downgraded the stock.
The post Seelos Downgraded After Phase 2 Trial Failure appeared first on Green Market…
After an unfavorable outcome in a clinical trial, Seelos Therapeutics Inc. (Nasdaq: SEEL) saw its stock price plummet on Wednesday, falling 70% after news. Thursday continued the downward trend during pre-market trading after Cantor Fitzgerald downgraded the stock.
SLS-002, the company’s investigational psychedelic therapy, was aimed at alleviating suicidal symptoms in adults diagnosed with major depressive disorder. However, the 147-patient Phase 2 trial failed to achieve meaningful signals for its primary endpoint.
Financial constraints, which led to a failure in meeting the enrollment target, were cited by Seelos as the primary reason for the trial’s setback.
Charles Duncan, a Cantor analyst, subsequently downgraded Seelos from “Overweight” to “Neutral.” Duncan pointed out that the company’s financial limitations could obstruct its ability to effectively conduct and complete such trials in the future.
Furthermore, given the uncertainties concerning the regulatory response to the data, which might be addressed in a forthcoming meeting with the Food and Drug Administration, Duncan chose a conservative approach. He’s opted to remain neutral and has suspended his previous $2 per share target price.
The post Seelos Downgraded After Phase 2 Trial Failure appeared first on Green Market Report.
psychedelic trading nasdaq seelos therapeutics seelos-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID